Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 7, 2014, Pages 1021-1025

  Holter Chakrabarty, Jennifer L ^a   Rubinger, Morel ^b   Le Rademacher, Jennifer ^c   Wang, Hai Lin ^c   Grigg, Andrew ^d   Selby, George B ^a   Szer, Jeffrey ^b   Rowe, Jacob M ^e   Weisdorf, Daniel J ^f   Tallman, Martin S ^g  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b Department of Hematology CancerCare Manitoba ^*  (Australia)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d AUSTIN HOSPITAL   (Australia)

^e RAMBAM MEDICAL CENTER   (Israel)

^f UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Allogeneic transplantation; APL; Autologous transplantation

Indexed keywords

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER PATIENT; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROMYELOCYTIC LEUKEMIA; RETROSPECTIVE STUDY; TREATMENT FAILURE; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, PROMYELOCYTIC, ACUTE; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; REMISSION; YOUNG ADULT;

ADULT; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84902013723     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.03.025     Document Type: Article

References (13)

1. Nabhan C., Mehta J., Tallman M.S. The role of bone marrow transplantation in acute promyelocytic leukemia. Bone Marrow Transplant 2001, 28:219-226.
2. Tallman M.S. Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies. Blood Rev 2001, 15:133-142.
3. Mandelli F., Diverio D., Awisati G., et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997, 90:1014-1021.
4. Soignet S.L., Frankel S.R., Douer D., et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001, 19:3852-3860.
5. Soignet S.L., Maslak P., Wang Z.G., et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998, 339:1341-1348.
6. Jurcic J.G., Nimer S.D., Scheinberg D.A., et al. Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia. Blood 2001, 98:2651-2656.
7. Grimwade D., Tallman M.S. Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia?. Leuk Res 2011, 35:3-7.
8. Sanz M.A., Labopin M., Gorin N.C., et al. Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2007, 39:461-469.
9. Meloni G., Diverio D., Vignetti M., et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. Blood 1997, 90:1321-1325.
10. Sanz M.A., de la Rubia J., Bonanad S., et al. Prolonged molecular remission after PML/RAR alpha-positive autologous peripheral blood stem cell transplantation in acute promyelocytic leukemia: is relevant pretransplant minimal residual disease in the graft?. Leukemia 1998, 12:992-995.
11. Yanada M., Tsuzuki M., Fujita H., et al. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood 2013, 121:3095-3102.
12. Wang J.C., Dick J.E. Cancer stem cells: lessons from leukemia. Trends Cell Biol 2005, 15:494-501.
13. Estey E., Garcia-Manero G., Ferrajoli A., et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006, 107:3469-3473.